Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

A randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, pharmacokinetics and pharmacodynamics of a novel menin inhibitor, balomenib (ZE63-0302): Interim analysis.

Amy Burd, Brian Ledwith, Megan Johnstone, Erin Hertlein, Alexander Khvat, Ola Elgamal, Ruben Karapetian, Kate Dokukina, Fraser Pickersgill, Peter Schrader, Nikolay Savchuk, Iain Dukes, John Byrd

Blood (2025) 146 (Supplement 1): 5067.

https://doi.org/10.1182/blood-2025-5067

Published: 2025

Journal Articles

A novel: Plasma apoptosis assay to demonstrate CLL cell target engagement in first-in-human study of a highly selective oral bcl-2 inhibitor lonitoclax (ZE50-0134)

John Byrd, Brian Ledwith, Fraser Pickersgill, Kate Dokukina, Ruben Karapetian, Chia Sharpe, Erin Hertlein, Megan Johnstone, Alexei Pushechnikov, Christopher Argent, Nikolay Savchuk, Iain Dukes, Amy Burd

Blood (2025) 146 (Supplement 1): 6819.

https://doi.org/10.1182/blood-2025-6819

Published: 2025

Journal Articles

A healthy volunteer study with lomonitinib predicts pharmacokinetics and pharmacodynamics in a relapsed refractory AML study

Blood (2025) 146 (Supplement 1): 6781.

https://doi.org/10.1182/blood-2025-6781

Published: 2025

Journal Articles

ZE74-0282 is a novel JH2 domain JAK2 inhibitor with promising pre-clinical activity in JAK2 V617F mutant diseases

Shailaja Hegde, Alexander Khvat, Ruben Karapetian, Brian Ledwith, Fraser Pickersgill, Megan Johnstone, Eric Vick, Emily Curran, Iain Dukes, Amy Burd, Nikolay Savchuk, Vladislav Parchincky, Igor Rezekin, Erin Hertlein, John Byrd

Blood (2025) 146 (Supplement 1): 1988.

https://doi.org/10.1182/blood-2025-1988

Published: 2025

Journal Articles

Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy

Erin Hertlein, Chad Bennett, Ola A Elgamal, Sandip Vibhute, Sharyn Baker, Thomas E Goodwin, Don M. Benson, Jr., Christopher Coss, Jeffrey Patrick, Gerald Hilinski, John C. Byrd

Blood (2022) 140 (Supplement 1): 10695–10696.

https://doi.org/10.1182/blood-2022-167671

Published: 2022

Journal Articles

Age and Sex Differences in the Eμ-TCL1 Adoptive Transfer Mouse Model of CLL

Chia Sharpe, Elizabeth Perry, Erin Hertlein, Natarajan Muthusamy, John C. Byrd

Blood (2022) 140 (Supplement 1): 12367–12368.

https://doi.org/10.1182/blood-2022-162900

Published: 2022

Journal Articles

Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia

Sydney Fobare, Shelley Orwick, Jessica Kohlschmidt, Tom Sesterhenn, Krzysztof Mrózek, Ben Wronowski, Megan Johnstone, Andrew J. Carroll, Richard M. Stone, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, John P Perentesis, Ann-Kathrin Eisfeld, Erin Hertlein, John C. Byrd

Blood (2022) 140 (Supplement 1): 743–744.

https://doi.org/10.1182/blood-2022-160323

Published: 2022

Journal Articles

A Novel Inhibitor of FLT3 and Its Drug-Resistant Mutants with Superior Activity to Gilteritinib in Molm-13 Preclinical Acute Myeloid Leukemia Xenograft Model

Blood (2022) 140 (Supplement 1): 3352–3353.

https://doi.org/10.1182/blood-2022-165675

Published: 2022

Journal Articles

Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies

Sara Elgamal, Tracy Clevenger, Michael Gulrajani, Jean Cheung, Erin G. Jeremy, Sydney Fobare, Shelley Orwick, Ellen J. Sass, Erin Hertlein, Karilyn T. Larkin, Todd Covey, Wayne P. Rothbaum, John C. Byrd

Blood (2022) 140 (Supplement 1): 5936–5938.

https://doi.org/10.1182/blood-2022-159568

Published: 2022

Journal Articles

A Novel Ptpn11 E76K / Npm1 cA Murine Model of AML Identifies a Unique Immune Population Relevant to Human Disease

Sydney Fobare, Chia Sharpe, Carolyn Cheney, Allison Mullaney, Casie Furby, Marissa Long, Jean Truxall, Megan Johnstone, Ann-Kathrin Eisfeld, John C. Byrd, Erin Hertlein

Blood (2022) 140 (Supplement 1): 5831–5832.

https://doi.org/10.1182/blood-2022-160093

Published: 2022

Journal Articles

Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia

Ola A Elgamal, Sandip Vibhute, Blaise Stearns, Susheela Tridandapani, Thomas E Goodwin, Gerard Hilinski, Chad Bennett, Jeffrey Patrick, Erin Hertlein, John C. Byrd

Blood (2022) 140 (Supplement 1): 3322–3323.

https://doi.org/10.1182/blood-2022-165611

Published: 2022

Journal Articles

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia

Blood (2022) 139 (9): 1340–1358.

https://doi.org/10.1182/blood.2020010344

Published: 2022

Includes: Supplemental data

Journal Articles

Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)

Sydney Fobare, Jessica Kohlschmidt, PhD, Hatice Gulcin Ozer, PhD, Krzysztof Mrózek, MDPhD, Deedra Nicolet, MS, Alice S. Mims, MD, Ramiro Garzon, MD, James S. Blachly, MD, Shelley Orwick, BS, Andrew J Carroll, PhD, Richard M. Stone, MD, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Christopher C. Oakes, PhD, Ann-Kathrin Eisfeld, MD, Erin Hertlein, PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-135887

Published: 2020

Journal Articles

NF-κB p50 ( nfkb1 ) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia

Timothy L. Chen, Minh Tran, Aparna Lakshmanan, Bonnie K. Harrington, Nikhil Gupta, Virginia M. Goettl, Amy M. Lehman, Stephen Trudeau, David M. Lucas, Amy J. Johnson, John C. Byrd, Erin Hertlein

Blood (2017) 130 (3): 376–379.

https://doi.org/10.1182/blood-2017-01-761130

Published: 2017

Includes: Supplemental data

Journal Articles

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

Ta-Ming Liu, Yonghua Ling, Jennifer A. Woyach, Kyle Beckwith, Yuh-Ying Yeh, Erin Hertlein, Xiaoli Zhang, Amy Lehman, Farrukh Awan, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Jessica MacMurray, Santosh B. Salunke, Ching-Shih Chen, Mitch A. Phelps, John C. Byrd, Amy J. Johnson

Blood (2015) 125 (2): 284–295.

https://doi.org/10.1182/blood-2014-06-583518

Published: 2015

Includes: Supplemental data

Journal Articles

A FOXy target in B-cell survival

Erin Hertlein

Blood (2014) 124 (23): 3340–3341.

https://doi.org/10.1182/blood-2014-10-605014

Published: 2014

Journal Articles

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Sarah E. M. Herman, Amber L. Gordon, Erin Hertlein, Asha Ramanunni, Xiaoli Zhang, Samantha Jaglowski, Joseph Flynn, Jeffrey Jones, Kristie A. Blum, Joseph J. Buggy, Ahmed Hamdy, Amy J. Johnson, John C. Byrd

Blood (2011) 117 (23): 6287–6296.

https://doi.org/10.1182/blood-2011-01-328484

Published: 2011

Journal Articles

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

Lapo Alinari, Bo Yu, Beth A. Christian, Fengting Yan, Jungook Shin, Rosa Lapalombella, Erin Hertlein, Mark E. Lustberg, Carl Quinion, Xiaoli Zhang, Gerard Lozanski, Natarajan Muthusamy, Mette Prætorius-Ibba, Owen A. O'Connor, David M. Goldenberg, John C. Byrd, Kristie A. Blum, Robert A. Baiocchi

Blood (2011) 117 (17): 4530–4541.

https://doi.org/10.1182/blood-2010-08-303354

Published: 2011

Includes: Supplemental data

Journal Articles

Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells

Erin Hertlein, Georgia Triantafillou, Ellen J. Sass, Joshua D. Hessler, Xiaoli Zhang, David Jarjoura, David M. Lucas, Natarajan Muthusamy, David M. Goldenberg, Robert J. Lee, John C. Byrd

Blood (2010) 116 (14): 2554–2558.

https://doi.org/10.1182/blood-2009-11-253203

Published: 2010

Includes: Supplemental data

Journal Articles

17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition

Erin Hertlein, Amy J. Wagner, Jeffrey Jones, Thomas S. Lin, Kami J. Maddocks, William H. Towns, III, Virginia M. Goettl, Xiaoli Zhang, David Jarjoura, Chelsey A. Raymond, Derek A. West, Carlo M. Croce, John C. Byrd, Amy J. Johnson

Blood (2010) 116 (1): 45–53.

https://doi.org/10.1182/blood-2010-01-263756

Published: 2010

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, pharmacokinetics and pharmacodynamics of a novel menin inhibitor, balomenib (ZE63-0302): Interim analysis.

A novel: Plasma apoptosis assay to demonstrate CLL cell target engagement in first-in-human study of a highly selective oral bcl-2 inhibitor lonitoclax (ZE50-0134)

A healthy volunteer study with lomonitinib predicts pharmacokinetics and pharmacodynamics in a relapsed refractory AML study

ZE74-0282 is a novel JH2 domain JAK2 inhibitor with promising pre-clinical activity in JAK2 V617F mutant diseases

Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy

Age and Sex Differences in the Eμ-TCL1 Adoptive Transfer Mouse Model of CLL

Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia

A Novel Inhibitor of FLT3 and Its Drug-Resistant Mutants with Superior Activity to Gilteritinib in Molm-13 Preclinical Acute Myeloid Leukemia Xenograft Model

Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies

A Novel Ptpn11 E76K / Npm1 cA Murine Model of AML Identifies a Unique Immune Population Relevant to Human Disease

Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia

Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)

NF-κB p50 ( nfkb1 ) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

A FOXy target in B-cell survival

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells

17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only